179 related articles for article (PubMed ID: 27069161)
1. Serum Thymidine Kinase 1 Activity Following Nephrectomy for Renal Cell Carcinoma and Radiofrequency Ablation of Metastases to Lung and Liver.
Nisman B; Appelbaum L; Yutkin V; Nechushtan H; Hubert A; Uziely B; Pode D; Peretz T
Anticancer Res; 2016 Apr; 36(4):1791-7. PubMed ID: 27069161
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy.
Nisman B; Yutkin V; Nechushtan H; Gofrit ON; Peretz T; Gronowitz S; Pode D
Urology; 2010 Aug; 76(2):513.e1-6. PubMed ID: 20573390
[TBL] [Abstract][Full Text] [Related]
3. Serum thymidine kinase 1 activity in the prognosis and monitoring of chemotherapy in lung cancer patients: a brief report.
Nisman B; Nechushtan H; Biran H; Gantz-Sorotsky H; Peled N; Gronowitz S; Peretz T
J Thorac Oncol; 2014 Oct; 9(10):1568-72. PubMed ID: 25521401
[TBL] [Abstract][Full Text] [Related]
4. Cancer-free survival and local tumor control after impendence-based radiofrequency ablation of biopsy-proven renal cell carcinomas with a minimum of 1-year follow-up.
Forauer AR; Dewey BJ; Seigne JD
Urol Oncol; 2014 Aug; 32(6):869-76. PubMed ID: 24946958
[TBL] [Abstract][Full Text] [Related]
5. Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma.
Psutka SP; Feldman AS; McDougal WS; McGovern FJ; Mueller P; Gervais DA
Eur Urol; 2013 Mar; 63(3):486-92. PubMed ID: 22959191
[TBL] [Abstract][Full Text] [Related]
6. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses.
Thompson RH; Atwell T; Schmit G; Lohse CM; Kurup AN; Weisbrod A; Psutka SP; Stewart SB; Callstrom MR; Cheville JC; Boorjian SA; Leibovich BC
Eur Urol; 2015 Feb; 67(2):252-9. PubMed ID: 25108580
[TBL] [Abstract][Full Text] [Related]
7. Percutaneous radiofrequency thermal ablation of renal cell carcinoma: is it possible a day-hospital treatment?
Carrafiello G; Laganà D; Ianniello A; Mangini M; Fontana F; Cotta E; Concollato L; Marconi A; Recaldini C; Dionigi G; Rovera F; Boni L; Cuffari S; Fugazzola C
Int J Surg; 2008; 6 Suppl 1():S31-5. PubMed ID: 19200792
[TBL] [Abstract][Full Text] [Related]
8. Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker.
Luo P; He E; Eriksson S; Zhou J; Hu G; Zhang J; Skog S
Eur J Cancer Prev; 2009 Jun; 18(3):220-4. PubMed ID: 19282758
[TBL] [Abstract][Full Text] [Related]
9. Radiofrequency ablation versus partial nephrectomy in patients with solitary clinical T1a renal cell carcinoma: comparable oncologic outcomes at a minimum of 5 years of follow-up.
Olweny EO; Park SK; Tan YK; Best SL; Trimmer C; Cadeddu JA
Eur Urol; 2012 Jun; 61(6):1156-61. PubMed ID: 22257424
[TBL] [Abstract][Full Text] [Related]
10. Percutaneous radiofrequency ablation for unresectable pulmonary metastases from renal cell carcinoma.
Soga N; Yamakado K; Gohara H; Takaki H; Hiraki T; Yamada T; Arima K; Takeda K; Kanazawa S; Sugimura Y
BJU Int; 2009 Sep; 104(6):790-4. PubMed ID: 19338555
[TBL] [Abstract][Full Text] [Related]
11. Comparison of percutaneous radiofrequency ablation and open partial nephrectomy for the treatment of size- and location-matched renal masses.
Sung HH; Park BK; Kim CK; Choi HY; Lee HM
Int J Hyperthermia; 2012; 28(3):227-34. PubMed ID: 22515344
[TBL] [Abstract][Full Text] [Related]
12. Treatment of pulmonary colorectal metastases by radiofrequency ablation.
Petre EN; Jia X; Thornton RH; Sofocleous CT; Alago W; Kemeny NE; Solomon SB
Clin Colorectal Cancer; 2013 Mar; 12(1):37-44. PubMed ID: 23026111
[TBL] [Abstract][Full Text] [Related]
13. Radiofrequency ablation versus radical nephrectomy: clinical outcomes for stage T1b renal cell carcinoma.
Takaki H; Soga N; Kanda H; Nakatsuka A; Uraki J; Fujimori M; Yamanaka T; Hasegawa T; Arima K; Sugimura Y; Sakuma H; Yamakado K
Radiology; 2014 Jan; 270(1):292-9. PubMed ID: 23925272
[TBL] [Abstract][Full Text] [Related]
14. [A case of interferon-alpha-resistant renal cell carcinoma responding to interleukin-2 therapy].
Kobori G; Yamada H; Higashi Y
Hinyokika Kiyo; 2008 Oct; 54(10):657-9. PubMed ID: 19048930
[TBL] [Abstract][Full Text] [Related]
15. Use of percutaneous radiofrequency ablation in pulmonary metastases from renal cell carcinoma.
Shu Yan Huo A; Lawson Morris D; King J; Glenn D
Ann Surg Oncol; 2009 Nov; 16(11):3169-75. PubMed ID: 19680727
[TBL] [Abstract][Full Text] [Related]
16. Post-radiofrequency ablation syndrome after percutaneous radiofrequency of abdominal tumours: one centre experience and review of published works.
Carrafiello G; Laganà D; Ianniello A; Dionigi G; Novario R; Recaldini C; Mangini M; Cuffari S; Fugazzola C
Australas Radiol; 2007 Dec; 51(6):550-4. PubMed ID: 17958690
[TBL] [Abstract][Full Text] [Related]
17. Preserved renal function after percutaneous radiofrequency ablation for renal tumors: experience of a single institution.
Ofude M; Kitagawa Y; Koda W; Ueno S; Kadono Y; Konaka H; Mizokami A; Gabata T; Namiki M
Anticancer Res; 2013 Oct; 33(10):4669-73. PubMed ID: 24123047
[TBL] [Abstract][Full Text] [Related]
18. Renal tumour nephrometry score does not correlate with the risk of radiofrequency ablation complications.
Seideman CA; Gahan J; Weaver M; Olweny EO; Richter M; Chan D; Cadeddu JA
BJU Int; 2013 Dec; 112(8):1121-4. PubMed ID: 24053576
[TBL] [Abstract][Full Text] [Related]
19. Hepatectomy and lung radiofrequency ablation for hepatic and subsequent pulmonary metastases from colorectal carcinoma.
Yan TD; King J; Ebrahimi A; Sjarif A; Glenn D; Steinke K; Morris DL
J Surg Oncol; 2007 Oct; 96(5):367-73. PubMed ID: 17443735
[TBL] [Abstract][Full Text] [Related]
20. Percutaneous radiofrequency ablation of renal tumors in solitary kidney patients.
Jiménez E; Zurera L; Espejo JJ; Requena MJ; Campos P; Rodríguez de Tembleque L; Canis M
Arch Esp Urol; 2011; 64(1):51-8. PubMed ID: 21289386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
